ArticleInvestigative ophthalmology & visual science2025
Genetic Associations of Rod- and Cone-Mediated Vision in Aging and Age-Related Macular Degeneration.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Science of Rod-Mediated Dark Adaptation, an Outcome Measure for Age-Related Macular Degeneration: The 2025 Proctor Medal Lecture.Investigative ophthalmology & visual science · 2026Article
- Choriocapillaris Flow Signal Deficits Are Associated With AMD Onset and Early Progression Over Three Years: ALSTAR2 Follow-Up.Investigative ophthalmology & visual science · 2026Article
- Preserved Contrast Sensitivity in Early and Intermediate Age-Related Macular Degeneration and Marked Loss in Late Stage: ALSTAR2.Investigative ophthalmology & visual science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose: To compare genetic associations of rod- and cone-driven vision with those previously defined for delayed rod-mediated dark adaptation (RMDA), a functional risk indicator for incident age-related macular degeneration (AMD). Methods: In adults aged ≥60 years with two normal eyes (per the Age-Related Eye Disease Study 9-step scale) or with AMD in one or both eyes, we measured RMDA at 5° superior retina, photopic vision (acuity, contrast sensitivity, light sensitivity), and mesopic vision (low luminance acuity and deficit). Vision associations of risk-conferring single-nucleotide polymorphisms in CFH and ARMS2 genes were adjusted for age and smoking and stratified for the presence of subretinal drusenoid deposit (SDD). Results: Of 608 participants, 462 had normal maculas and 146 had AMD. Neither ARMS2 nor CFH was significantly associated with AMD stage. Across all eyes, RMDA worsened significantly in association with ARMS2 (P = 0.0005). Associations were stronger in normal eyes than in AMD (P = 0.0012 vs. 0.0580) and in normal eyes lacking SDD (n = 384, P < 0.0024). Across all eyes, RMDA was significantly associated with CFH (P = 0.0023) but not in normal and AMD eyes separately (P = 0.270 vs. 0.0596). RMDA was significantly associated with the number of risk alleles in normal and AMD eyes (P < 0.0001). Low luminance deficit was associated with gene dose for AMD eyes only (P = 0.477). Conclusions: Of six vision tests, only RMDA was consistently associated with major risk alleles, including ARMS2 (not CFH) in normal eyes, with or without SDD. RMDA assesses dynamic retinoid resupply from the circulation, perhaps presaging SDD. Results are interpreted considering localization of key proteins in Bruch's membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.